haloperidol has been researched along with paroxetine in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 11 (26.83) | 18.2507 |
| 2000's | 17 (41.46) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goodman, MM; Kabalka, GW; Kung, HF; Kung, MP; Switzer, R | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Cooper, SM; Jackson, D; Loudon, JM; McClelland, GR; Raptopoulos, P | 1 |
| Bruun, RD; Budman, CL; Sherling, M | 1 |
| Bergeron, R; De Montigny, C; Debonnel, G | 1 |
| Copolov, D; Dean, B; Hill, C; Keks, N; Naylor, L; Opeskin, K; Pavey, G | 1 |
| König, F; Löble, M; Wolfersdorf, M | 1 |
| Earley, B; Faherty, CJ; Leonard, BE | 1 |
| Bøgesø, KP; Dannals, RF; Hatzidimitriou, G; Ravert, HT; Ricaurte, GA; Scheffel, UA; Suehiro, M; Wagner, HN | 1 |
| Christenson, GA; Keuthen, NJ; Mansueto, CS; O'Sullivan, RL; Stein, DJ; Swedo, SE | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; Martín, AB; O'Shea, E | 1 |
| Fujiseki, Y; Inagaki, C; Kinoshita, T; Okugawa, G; Omori, K; Suzukawa, J | 1 |
| Bottlender, R; Möller, HJ | 1 |
| Bell, R; Campbell, C; Green, JF; King, DJ; McCartan, D; Pickering, A; Trimble, K | 1 |
| Rehavi, M; Roz, N; Weizman, A | 1 |
| König, F; Raape, J; Truöl, S; Von Hippel, C | 1 |
| Gaisler-Salomon, I; Green, A; Joel, D; Schiller, D; Weiner, I | 1 |
| Bonikovski, V; Futuro-Neto, HA; Pires, JG | 1 |
| de Bruijn, ER; Hulstijn, W; Ruigt, GS; Sabbe, BG; Verkes, RJ | 1 |
| Hulstijn, W; Morrens, M; Ruigt, GS; Sabbe, BG; Verkes, RJ; Wezenberg, E | 1 |
| Alfirevic, Z; Degoricija, V; Vucicevic, Z; Vukicevic-Badouin, D | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Asukai, N; Haraguchi, A; Hori, T; Ikeda, K; Ogai, Y; Senoo, E | 1 |
| Gurwitz, D; Morag, A; Oved, K | 1 |
1 review(s) available for haloperidol and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for haloperidol and paroxetine
| Article | Year |
|---|---|
The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol.
Topics: Adult; Amobarbital; Antidepressive Agents; Arousal; Double-Blind Method; Ethanol; Female; Haloperidol; Humans; Male; Middle Aged; Oxazepam; Paroxetine; Piperidines; Psychomotor Performance; Randomized Controlled Trials as Topic; Reaction Time; Serotonin Antagonists | 1989 |
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers.
Topics: Acoustic Stimulation; Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Chlorpromazine; Cognition; Double-Blind Method; Haloperidol; Humans; Learning; Lorazepam; Male; Neuropsychological Tests; Paroxetine; Psychomotor Performance; Space Perception | 2001 |
Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Contingent Negative Variation; Double-Blind Method; Electroencephalography; Female; Haloperidol; Humans; Linear Models; Male; Monitoring, Physiologic; Olanzapine; Paroxetine; Reaction Time | 2006 |
Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Memory; Olanzapine; Paroxetine; Psychomotor Performance; Reference Values | 2007 |
36 other study(ies) available for haloperidol and paroxetine
| Article | Year |
|---|---|
Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; In Vitro Techniques; Iodine Radioisotopes; Isotope Labeling; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Protein Binding; Rats; Rats, Sprague-Dawley; Stereoisomerism; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tropanes | 1994 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Combined pharmacotherapy risk.
Topics: Child; Drug Therapy, Combination; Haloperidol; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tourette Syndrome | 1995 |
Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Topics: 1-Naphthylamine; Animals; Antidepressive Agents; Clorgyline; Electrophysiology; Haloperidol; Male; N-Methylaspartate; Paroxetine; Pyramidal Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sertraline; Tranylcypromine | 1993 |
Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Binding, Competitive; Carrier Proteins; Female; Haloperidol; Hippocampus; Humans; Male; Membrane Glycoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Suicide; Tritium | 1996 |
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzamides; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Trimipramine | 1996 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
Highly potent indanamine serotonin uptake blockers as radiotracers for imaging serotonin uptake sites.
Topics: Animals; Autoradiography; Brain; Haloperidol; Indans; Mice; Paroxetine; Radiopharmaceuticals; Rats; Selective Serotonin Reuptake Inhibitors; Tissue Distribution | 1994 |
Trichotillomania: behavioral symptom or clinical syndrome?
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Female; Haloperidol; Humans; Paroxetine; Trichotillomania | 1997 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Serotonin | 1999 |
Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Cells, Cultured; Desipramine; Dexamethasone; Gene Expression Regulation; Haloperidol; Hippocampus; Ketanserin; Mianserin; Neurons; Paroxetine; Phentolamine; Propranolol; Radioligand Assay; Rats; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; RNA, Messenger; Sulpiride; Transcription, Genetic; Tritium | 1999 |
Negative symptoms due to sleep apnea syndrome in a patient with a delusional disorder.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Delusions; Haloperidol; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Severity of Illness Index; Sleep Apnea Syndromes | 1999 |
Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Topics: Animals; Antipsychotic Agents; Binding Sites; Biological Transport; Brain; Brain Chemistry; Clozapine; Drug Administration Schedule; Fluoxetine; Haloperidol; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Paroxetine; Piperazines; Rats; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2002 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Neurologic Examination; Olanzapine; Paroxetine; Patient Admission; Pirenzepine | 2002 |
A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clozapine; Conditioning, Psychological; Haloperidol; Imipramine; Inhibition, Psychological; Male; Models, Animal; Olanzapine; Paroxetine; Pirenzepine; Rats; Rats, Wistar; Swimming | 2003 |
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Disease Models, Animal; Female; Fluoxetine; Haloperidol; Male; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Time Factors | 2005 |
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Edema; Fatal Outcome; Fluphenazine; Haloperidol; Heart Arrest; Humans; Hyperglycemia; Hyponatremia; Inappropriate ADH Syndrome; Male; Mental Disorders; Olanzapine; Pancreatitis; Paroxetine; Polypharmacy; Selective Serotonin Reuptake Inhibitors | 2007 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Influence of GIRK channel inhibition on alcohol abstinence and relapse risk in Japanese alcohol-dependent outpatients.
Topics: Alcoholism; Analysis of Variance; Asian People; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Haloperidol; Humans; Middle Aged; Outpatients; Paroxetine; Piperidines; Retrospective Studies; Risk; Secondary Prevention; Treatment Outcome | 2011 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell Division; Cell Survival; Cells, Cultured; Cytostatic Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Dystonic Disorders; Female; Haloperidol; Humans; Lymphocytes; Male; Paroxetine; Risperidone; Schizophrenia; Sex Characteristics; Sex Distribution | 2013 |